Abeona Therapeutics Sees Unusually Large Options Volume (NASDAQ:ABEO)

Abeona Therapeutics Inc (NASDAQ:ABEO) was the target of unusually large options trading on Monday. Stock traders acquired 5,499 call options on the stock. This represents an increase of approximately 657% compared to the typical volume of 726 call options.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ABEO. Oppenheimer began coverage on Abeona Therapeutics in a report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price objective for the company. HC Wainwright increased their target price on Abeona Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, April 30th. Finally, StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 24th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.75.

Abeona Therapeutics Stock Up 6.3%

Shares of NASDAQ:ABEO opened at $5.60 on Tuesday. Abeona Therapeutics has a 52-week low of $3.93 and a 52-week high of $7.32. The firm has a market capitalization of $273.28 million, a P/E ratio of -2.08 and a beta of 1.68. The stock has a 50 day moving average price of $5.14 and a 200-day moving average price of $5.57. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.19. As a group, equities research analysts anticipate that Abeona Therapeutics will post -1.16 EPS for the current fiscal year.

Insiders Place Their Bets

In other Abeona Therapeutics news, CEO Vishwas Seshadri sold 25,000 shares of the stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $4.78, for a total value of $119,500.00. Following the completion of the sale, the chief executive officer now owns 1,355,322 shares in the company, valued at approximately $6,478,439.16. This trade represents a 1.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Twinbeech Capital LP bought a new position in Abeona Therapeutics during the 4th quarter valued at approximately $58,000. Northern Trust Corp increased its position in Abeona Therapeutics by 6.6% during the 4th quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company’s stock valued at $1,030,000 after buying an additional 11,478 shares in the last quarter. Squarepoint Ops LLC bought a new position in Abeona Therapeutics during the 4th quarter valued at approximately $67,000. Jane Street Group LLC bought a new position in Abeona Therapeutics during the 3rd quarter valued at approximately $84,000. Finally, Cannon Global Investment Management LLC bought a new position in Abeona Therapeutics during the 1st quarter valued at approximately $67,000. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.